substantial benefits from early vaccination for flu pandemic

PharmacoEconomics & Outcomes News 706, p15 - 5 Jul 2014 Substantial benefits from early vaccination for flu pandemic Early vaccination for a human influenza A (H7N9) pandemic has substantial health and economic benefits, according to a study published in Annals of Internal Medicine. The study used a dynamic transmission model to evaluate the effectiveness and cost effectiveness of vaccination against influenza A (H7N9) at 4, 6 or 9 months, compared with no vaccination, for a population of 8.3 million persons in a large metropolitan city in the US. The analysis was conducted from a societal perspective. The model predicted that without vaccination, 1.92 million persons would become symptomatically infected and 48 254 would die. Vaccinating at 9 months would avert 2365 deaths. Vaccinating at 6 months, rather than at 9 months, would avert 5775 additional deaths, and would save $US51 million in treatment costs (2012 values); vaccinating at 4 months, rather than at 6 months, would avert 5633 additional deaths, and would save $50 million. The incremental costs of completing the vaccination programme at 6 rather than 9 months was estimated at $10 722/QALY saved, and completing the programme at 4 rather than 6 months would cost $10 689/QALY saved. The study also showed that the benefits of non-pharmaceutical interventions, such as hand washing, home isolation and cough etiquette, were substantial. Khazeni N, et al. Health and Economic Benefits of Early Vaccination and Nonpharmaceutical Interventions for a Human Influenza A (H7N9) Pandemic: A Modeling Study. Annals of Internal Medicine : 20 May 2014. Available from: URL: http://annals.org/article.aspx?articleid=1872847 803105482 1 PharmacoEconomics & Outcomes News 5 Jul 2014 No. 706 1173-5503/14/0706-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved

Upload: ngobao

Post on 18-Mar-2017

215 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

PharmacoEconomics & Outcomes News 706, p15 - 5 Jul 2014

Substantial benefits from earlyvaccination for flu pandemic

Early vaccination for a human influenza A (H7N9)pandemic has substantial health and economic benefits,according to a study published in Annals of InternalMedicine.

The study used a dynamic transmission model toevaluate the effectiveness and cost effectiveness ofvaccination against influenza A (H7N9) at 4, 6 or9 months, compared with no vaccination, for apopulation of 8.3 million persons in a large metropolitancity in the US. The analysis was conducted from asocietal perspective.

The model predicted that without vaccination,1.92 million persons would become symptomaticallyinfected and 48 254 would die. Vaccinating at 9 monthswould avert 2365 deaths. Vaccinating at 6 months,rather than at 9 months, would avert 5775 additionaldeaths, and would save $US51 million in treatmentcosts (2012 values); vaccinating at 4 months, rather thanat 6 months, would avert 5633 additional deaths, andwould save $50 million. The incremental costs ofcompleting the vaccination programme at 6 rather than9 months was estimated at $10 722/QALY saved, andcompleting the programme at 4 rather than 6 monthswould cost $10 689/QALY saved. The study also showedthat the benefits of non-pharmaceutical interventions,such as hand washing, home isolation and coughetiquette, were substantial.Khazeni N, et al. Health and Economic Benefits of Early Vaccination andNonpharmaceutical Interventions for a Human Influenza A (H7N9) Pandemic: AModeling Study. Annals of Internal Medicine : 20 May 2014. Available from:URL: http://annals.org/article.aspx?articleid=1872847 803105482

1

PharmacoEconomics & Outcomes News 5 Jul 2014 No. 7061173-5503/14/0706-0001/$14.95 Adis 2014 Springer International Publishing AG. All rights reserved